<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right; font-weight: bold;">Registration Statement No.</div>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
      <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">UNDER</div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">GALECTIN THERAPEUTICS INC.</div>
      <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z34b8a2ac2a3243108776ac09d9f849ed">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nevada</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;"><br>
            </td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">04-3562325</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or Other Jurisdiction of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Incorporation or Organization)</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;"><br>
            </td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(I.R.S. Employer</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Identification No.)</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">4960 Peachtree Industrial Blvd., Suite 240</div>
      <div style="text-align: center; font-weight: bold;">Norcross, Georgia 30071</div>
      <div style="text-align: center; font-weight: bold;">(678) 620-3186</div>
      <div style="text-align: center; font-weight: bold;">(Address, including zip code, of registrant&#8217;s principal executive offices)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">2019 Omnibus Equity Incentive Plan, as amended</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Joel Lewis</div>
      <div style="text-align: center; font-weight: bold;">Chief Executive Officer and President</div>
      <div style="text-align: center; font-weight: bold;">Galectin Therapeutics Inc.</div>
      <div style="text-align: center; font-weight: bold;">4960 Peachtree Industrial Blvd., Suite 240</div>
      <div style="text-align: center; font-weight: bold;">Norcross, Georgia 30071</div>
      <div style="text-align: center; font-weight: bold;">(678) 620-3186</div>
      <div style="text-align: center; font-weight: bold;">(Name and address, including zip code, and telephone number, including area code, of agent for service)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">Copy to:</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zf500ac2425cb40f0be127e7bf79b3595">

          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Robert E. Tritt, Esq.</div>
              <div style="text-align: center; font-weight: bold;">Dentons US LLP</div>
              <div style="text-align: center; font-weight: bold;">303 Peachtree Street, NE</div>
              <div style="text-align: center; font-weight: bold;">Suite 5300</div>
              <div style="text-align: center; font-weight: bold;">Atlanta, GA 30308</div>
              <div style="text-align: center; font-weight: bold;">(404) 527-8130</div>
            </td>
            <td style="width: 50%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Brian Lee, Esq.</div>
              <div style="text-align: center; font-weight: bold;">Dentons US LLP</div>
              <div style="text-align: center; font-weight: bold;">1221 Avenue of the Americas</div>
              <div style="text-align: center; font-weight: bold;">New York, NY</div>
              <div style="text-align: center; font-weight: bold;">New York, NY 10020</div>
              <div style="text-align: center; font-weight: bold;">(212) 768-6926</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
        filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7b4a411172f54426902d4f4862c577b9">

          <tr>
            <td style="width: 13%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Large </div>
              <div style="color: rgb(0, 0, 0);">accelerated filer</div>
            </td>
            <td style="width: 70%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">&#9744;</div>
            </td>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Accelerated filer</div>
            </td>
            <td style="width: 2.41%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13%; vertical-align: middle;">&#160;</td>
            <td style="width: 70%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.41%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 13%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Non-accelerated </div>
              <div style="color: rgb(0, 0, 0);">filer</div>
            </td>
            <td style="width: 70%; vertical-align: bottom;">
              <div style="color: #000000;">&#9746; (Do not check if a smaller reporting company)</div>
            </td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Smaller reporting company</div>
            </td>
            <td style="width: 2.41%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">&#9746;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13%; vertical-align: middle;">&#160;</td>
            <td style="width: 70%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.41%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 13%; vertical-align: bottom;">&#160;</td>
            <td style="width: 70%; vertical-align: bottom;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Emerging growth company</div>
            </td>
            <td style="width: 2.41%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">&#9744;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
        Securities Act. &#9744;</div>
      <div>&#160;</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART I</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="text-align: center; color: #000000; font-weight: bold;">INFORMATION REQUIRED IN THIS PROSPECTUS</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;">Galectin Therapeutics Inc., a Nevada corporation (the &#8220;Company&#8221; or the &#8220;Registrant&#8221;), hereby files this Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) with the U.S. Securities and Exchange Commission
          (the &#8220;SEC&#8221;) to register up to 3,000,000 shares of the Registrant&#8217;s common stock, par value $0.001 per share, to be issued under the Registrant&#8217;s 2019 Omnibus Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), which Plan was approved by the
          Registrant&#8217;s shareholders at the Registrant&#8217;s 2019 annual meeting held on December 4, 2019 and which amendment thereto was approved by the Registrant&#8217;s shareholders at the Registrant&#8217;s 2021 annual meeting held on December 3, 2021. The information
          specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the
          &#8220;Securities Act&#8221;), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement
          as specified by Rule 428(b)(1) under the Securities Act.</div>
      </div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">PART II</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75a1d175f0f64c57b08536abbd740458">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 3.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Incorporation of Certain Documents by Reference.</div>
            </td>
          </tr>

      </table>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;">The following documents are incorporated by reference in the Registration Statement:</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;">(a) Our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1133416/000114036123014658/brhc10049486_10k.htm">March 30, 2023</a>;</div>
        <div>&#160;</div>
        <div style="color: #000000;">(b) Our Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1133416/000114036123009574/brhc10049140_8k.htm">March 2, 2023</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1133416/000114036123000580/brhc10046311_8k.htm">January 5, 2023</a>; and</div>
        <div>&#160;</div>
        <div style="color: #000000;">(c) The description of our common stock contained in our registration statement on Form 8-A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312503047012/d8a12b.htm">September 9,
            2003</a>, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including any amendments or reports filed for the purpose of updating that description, including Amendment No 1 to Form 8-A filed with
          the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312512126592/d320566d8a12ba.htm">March 22, 2012</a>.</div>
      </div>
      <div>&#160;</div>
      <div style="color: #000000;">All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that
        all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any
        statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other
        subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to
        constitute a part of this Registration Statement.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3505986d47c04c0eb5f8ac7dc2979512">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 4.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description of Securities</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Not applicable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaab0b74e3a2f48aa91073c674e7550ef">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 5.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Interests of Named Experts and Counsel.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Not applicable.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d46c044a5484faf9662a453b207016f">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 6.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Indemnification of Directors and Officers.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>The Registrant&#8217;s By-laws, as amended to date, provide for indemnification of officers and directors to the fullest extent permitted by Section 7502 of Chapter 78 of the Nevada Revised Statutes (&#8220;NRS&#8221;) (as from time to time amended), provided
        such officer or director acts in good faith and in a manner which such person reasonably believes to be in or not opposed to the best interests of the Registrant, and with respect to any criminal matter, had no reasonable cause to believe such
        person&#8217;s conduct was unlawful.</div>
      <div>&#160;</div>
      <div>NRS 78.7502 states:</div>
      <div>&#160;</div>
      <div>&#8220;1. A corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action
        by or in the right of the corporation, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
        another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action,
        suit or proceeding if the person:</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1dfff97b4a414076a9e2a52c716a9860">

          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(a)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Is not liable pursuant to NRS 78.138; or</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(b)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no
                reasonable cause to believe the conduct was unlawful.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of <font style="font-style: italic;">nolo contendere</font> or its equivalent, does not, of itself, create a presumption that the person
        is liable pursuant to NRS 78.138 or did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, or that, with respect to any criminal action or proceeding, he or
        she had reasonable cause to believe that the conduct was unlawful.</div>
      <div>&#160;</div>
      <div>2. A corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the
        fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
        other enterprise against expenses, including amounts paid in settlement and attorneys&#8217; fees actually and reasonably incurred by the person in connection with the defense or settlement of the action or suit if the person:</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7481469fe3b14e5691879f04745d0364">

          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(a)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Is not liable pursuant to NRS 78.138; or</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(b)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in
        settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person
        is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</div>
      <div>&#160;</div>
      <div>3. To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections 1 and 2, or in defense of any claim, issue or
        matter therein, the corporation shall indemnify him or her against expenses, including attorneys&#8217; fees, actually and reasonably incurred by him or her in connection with the defense.&#8221;</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>The Registrant&#8217;s By-laws also provide that to the fullest extent permitted by NRS 78.751 (as from time to time amended), the Registrant shall pay the expenses of officers and directors of the Corporation incurred in defending a civil or criminal
        action, suit or proceeding, as they are incurred and in advance of the final disposition of such matter, upon receipt of an undertaking in form and substance acceptable to the board of directors for the repayment of such advances if it is
        ultimately determined by a court of competent jurisdiction that the officer or director is not entitled to be indemnified.</div>
      <div>&#160;</div>
      <div>NRS 78.751 states:</div>
      <div>&#160;</div>
      <div>&#8220;1. Any discretionary indemnification pursuant to NRS 78.7502, unless ordered by a court or advanced pursuant to subsection 2, may be made by the corporation only as authorized in the specific case upon a determination that indemnification of
        the director, officer, employee or agent is proper in the circumstances. The determination must be made:</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z406ef2dfdb84427e95618680d01765aa">

          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(a)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By the stockholders;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(b)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By the board of directors by majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(c)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">If a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion; or</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(d)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">If a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>2. The articles of incorporation, the bylaws or an agreement made by the corporation may provide that the expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the corporation as
        they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent
        jurisdiction that the director or officer is not entitled to be indemnified by the corporation. The provisions of this subsection do not affect any rights to advancement of expenses to which corporate personnel other than directors or officers may
        be entitled under any contract or otherwise by law.</div>
      <div>&#160;</div>
      <div>3. The indemnification pursuant to NRS 78.7502 and advancement of expenses authorized in or ordered by a court pursuant to this section:</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze0e37c735580425d97296bd2443c641a">

          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(a)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Does not exclude any other rights to which a person seeking indemnification or advancement of expenses may be entitled under the articles of incorporation or any bylaw, agreement, vote of stockholders or
                disinterested directors or otherwise, for either an action in the person&#8217;s official capacity or an action in another capacity while holding office, except that indemnification, unless ordered by a court pursuant to NRS 78.7502 or for the
                advancement of expenses made pursuant to subsection 2, may not be made to or on behalf of any director or officer if a final adjudication establishes that the director&#8217;s or officer&#8217;s acts or omissions involved intentional misconduct, fraud
                or a knowing violation of the law and was material to the cause of action. A right to indemnification or to advancement of expenses arising under a provision of the articles of incorporation or any bylaw is not eliminated or impaired by an
                amendment to such provision after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought,
                unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: middle;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">(b)</div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Continues for a person who has ceased to be a director, officer, employee or agent and inures to the benefit of the heirs, executors and administrators of such a person.&#8221;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>In addition, the Registrant maintains directors&#8217; and officers&#8217; liability insurance which insures against liabilities that its directors and officers may incur in such capacities.</div>
      <div>&#160;</div>
      <div>Reference is made to &#8220;Undertakings,&#8221; below, for the Registrant&#8217;s undertakings in this registration statement with respect to indemnification of liabilities arising under the Securities Act.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z292e524987a045a98581a741739c397e">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 7.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exemption from Registration Claimed.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Not applicable.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8192d73ffc4841a8bcdebd4e3d5707e1">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 8.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibits.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8bca9605ba334fb0a552eb4d50ef04fb">

          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 7.06%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
              <div>
                <div style="text-align: center; font-weight: bold;">No.</div>
              </div>
            </td>
            <td rowspan="1" style="width: 2.55%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 90.38%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div>
                <div style="font-weight: bold;">Exhibit</div>
              </div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" rowspan="1" style="width: 7.06%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 2.55%; vertical-align: bottom;">&#160;</td>
            <td rowspan="1" style="width: 90.38%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;">
              <div>4.1</div>
            </td>
            <td style="width: 2.55%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;">
              <div style="color: rgb(0, 0, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312520237638/d944148dex102.htm">Deferred Stock Unit Agreement, dated August&#160; 31, 2020, between Galectin Therapeutics Inc. and Joel Lewis
                  (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the Commission on September 2, 2020)</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.06%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="width: 92.94%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;">
              <div>5.1*</div>
            </td>
            <td style="width: 2.55%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;">
              <div style="color: rgb(0, 0, 255);"><a href="brhc10050286_ex5-1.htm">Opinion of Dentons US LLP regarding legality</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.06%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="width: 92.94%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;">
              <div>23.1*</div>
            </td>
            <td style="width: 2.55%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;">
              <div style="color: rgb(0, 0, 255);"><a href="brhc10050286_ex5-1.htm">Consent of Dentons US LLP (included as part of Exhibit 5.1 hereto)</a></div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">23.2*</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1"><a href="brhc10050286_ex23-2.htm">Consent of Cherry Bekaert LLP</a></td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">24*</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1"><a href="#POA">Power of Attorney (included in the signature pages of this registration statement)</a></td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">99.1</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1"><a href="https://www.sec.gov/Archives/edgar/data/1133416/000119312519268920/d814474ddef14a.htm#toc814474_22">2019 Omnibus Equity Incentive Plan (Incorporated by reference to Appendix A
                of the Company&#8217;s Definitive Proxy Statement on Schedule 14A as filed with the Commission on October 17, 2019.)</a></td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">99.2</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1"><a href="https://www.sec.gov/Archives/edgar/data/1133416/000114036121034290/ny20000819x1_def14a.htm#tAPPA">Amendment to 2019 Omnibus Equity Incentive Plan (Incorporated by reference to
                Appendix B of the Company&#8217;s Definitive Proxy Statement on Schedule 14A as filed with the Commission on October 12, 2021.)</a></td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 7.06%; vertical-align: top;" rowspan="1">107*</td>
            <td style="width: 2.55%; vertical-align: bottom;" rowspan="1">&#160;</td>
            <td style="width: 90.38%; vertical-align: top;" rowspan="1"><a href="brhc10050286_ex107.htm">Filing Fee Table</a></td>
          </tr>

      </table>
      <div>
        <div><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0eeae841c9514c048e9ce1190fd5f312">

          <tr>
            <td style="width: 2%; vertical-align: top;">
              <div>*</div>
            </td>
            <td style="width: 98%; vertical-align: top;">
              <div>Filed herewith.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z57e8e410ac6845d0b10b3d361d28f88a">

          <tr>
            <td style="width: 53.5pt; vertical-align: top; color: #000000; font-weight: bold;">Item 9.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Undertakings.</div>
            </td>
          </tr>

      </table>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;">The undersigned registrant hereby undertakes:</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;">1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
        <div>&#160;</div>
        <div style="color: #000000;">(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
        <div>&#160;</div>
        <div style="color: #000000;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
          represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
          that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
          price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div>
        <div>&#160;</div>
        <div style="color: #000000;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div>
        <div>&#160;</div>
        <div style="color: #000000;"><font style="font-style: italic;">provided, however</font>, that paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those
          paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act, that are incorporated by reference in this registration statement, or is contained in a
          form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</div>
        <div>&#160;</div>
        <div style="color: #000000;">2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and this
          offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;</div>
        <div>&#160;</div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="color: #000000;">3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of this offering;</div>
        <div>&#160;</div>
        <div style="color: #000000;">4. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d)
          of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new
          registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
        <div>&#160;</div>
        <div style="color: #000000;">5. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6, or
          otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
          indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
          asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
          appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</div>
      </div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be
        signed on its behalf by the undersigned, thereunto duly authorized, in the City of Norcross, State of Georgia on March 30, 2023.</div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9c0f94f5d85b4a14927005b2a7b9aee6">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">GALECTIN THERAPEUTICS INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 47%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt; color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-indent: -10pt; margin-left: 10pt; color: rgb(0, 0, 0);">/s/ Joel Lewis</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="width: 47%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt; color: rgb(0, 0, 0);">Joel Lewis</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="width: 47%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt; color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>
          </tr>

      </table>
      <div>
        <div><br>
        </div>
        <div style="color: #000000;">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joel Lewis and Jack W. Callicutt and each of them, his or her true and lawful attorneys-in-fact and agents, with
          full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file
          the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and
          every act and thing requisite and necessary to be done in and about the premises, as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her
          substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</div>
        <div>&#160;</div>
        <div style="color: #000000;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div>
        <div>&#160;</div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="color: #000000;"><u><!--Anchor-->PRINCIPAL EXECUTIVE, FINANCIAL &amp; ACCOUNTING OFFICERS AND DIRECTORS</u>:<a name="POA"><!--Anchor--></a></div>
      </div>
      <div>
        <div><font style="color: rgb(0, 0, 0);"> </font><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze871aaa95b1e47998370aa26fefbd0a6">

          <tr>
            <td style="width: 37.96%; vertical-align: bottom;">
              <div style="font-weight: bold;">Name</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 44.95%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Title</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 15%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Joel Lewis</div>
              </div>
            </td>
            <td colspan="1" rowspan="2" style="width: 1%; vertical-align: top;">&#160;</td>
            <td rowspan="2" style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Chief Executive Officer (Principal Executive Officer)</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Joel Lewis</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Jack W. Callicutt</div>
              </div>
            </td>
            <td colspan="1" rowspan="2" style="width: 1%; vertical-align: top;">&#160;</td>
            <td rowspan="2" style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Jack W. Callicutt</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Richard E. Uihlein</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Chairman and Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Richard E. Uihlein</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Gilbert F. Amelio, Ph.D</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Gilbert F. Amelio, Ph.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ James C. Czirr</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>James C. Czirr</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Kary Eldred</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Kary Eldred</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Kevin D. Freeman</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Kevin D. Freeman, CFA</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Gilbert S. Omenn</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Gilbert S. Omenn, M.D., Ph.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Marc Rubin</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Marc Rubin, M.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Elissa J. Schwartz</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Elissa J. Schwartz, Ph.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Harold Shlevin</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Harold Shlevin, Ph.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.95%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Richard A. Zordani</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">
              <div style="text-indent: -12pt; margin-left: 12pt;">Director</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 15%; vertical-align: top;">
              <div style="text-align: center;">March 30, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 37.96%; vertical-align: top;">
              <div>Richard A. Zordani</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 44.95%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "brhc10050286_s8.htm", "description": "S-8", "secsgml_size_bytes": 74304}]
{"company-data": {"conformed-name": "GALECTIN THERAPEUTICS INC", "cik": "0001133416", "assigned-sic": "2834", "irs-number": "043562325", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-270981", "film-number": "23780545"}, "business-address": {"street1": "4960 PEACHTREE INDUSTRIAL BOULEVARD", "street2": "SUITE 240", "city": "NORCROSS", "state": "GA", "zip": "30071", "phone": "678-620-3186"}, "mail-address": {"street1": "4960 PEACHTREE INDUSTRIAL BOULEVARD", "street2": "SUITE 240", "city": "NORCROSS", "state": "GA", "zip": "30071"}, "former-company": {"former-conformed-name": "PRO PHARMACEUTICALS INC", "date-changed": "20010612"}}
Registration Statement No.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Nevada
04-3562325
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
4960 Peachtree Industrial Blvd., Suite 240
Norcross, Georgia 30071
(678) 620-3186
(Address, including zip code, of registrant's principal executive offices)
2019 Omnibus Equity Incentive Plan, as amended
Joel Lewis
Chief Executive Officer and President
Galectin Therapeutics Inc.
4960 Peachtree Industrial Blvd., Suite 240
Norcross, Georgia 30071
(678) 620-3186
(Name and address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Robert E. Tritt, Esq.
Dentons US LLP
303 Peachtree Street, NE
Suite 5300
Atlanta, GA 30308
(404) 527-8130
Brian Lee, Esq.
Dentons US LLP
1221 Avenue of the Americas
New York, NY
New York, NY 10020
(212) 768-6926
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
        filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
☐
Accelerated filer
☐
Non-accelerated
filer
☒ (Do not check if a smaller reporting company)
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
        Securities Act. ☐
PART I
INFORMATION REQUIRED IN THIS PROSPECTUS
Galectin Therapeutics Inc., a Nevada corporation (the "Company" or the "Registrant"), hereby files this Registration Statement on Form S-8 (this "Registration Statement") with the U.S. Securities and Exchange Commission
          (the "SEC") to register up to 3,000,000 shares of the Registrant's common stock, par value $0.001 per share, to be issued under the Registrant's 2019 Omnibus Equity Incentive Plan, as amended (the "Plan"), which Plan was approved by the
          Registrant's shareholders at the Registrant's 2019 annual meeting held on December 4, 2019 and which amendment thereto was approved by the Registrant's shareholders at the Registrant's 2021 annual meeting held on December 3, 2021. The information
          specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this "Registration Statement") in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the
          "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement
          as specified by Rule 428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Certain Documents by Reference.
The following documents are incorporated by reference in the Registration Statement:
(a) Our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on
March 30, 2023
;
(b) Our Current Reports on Form 8-K filed with the SEC on
March 2, 2023
and
January 5, 2023
; and
(c) The description of our common stock contained in our registration statement on Form 8-A filed with the SEC on
September 9,
            2003
, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendments or reports filed for the purpose of updating that description, including Amendment No 1 to Form 8-A filed with
          the SEC on
March 22, 2012
.
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that
        all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any
        statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other
        subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to
        constitute a part of this Registration Statement.
Item 4.
Description of Securities
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
The Registrant's By-laws, as amended to date, provide for indemnification of officers and directors to the fullest extent permitted by Section 7502 of Chapter 78 of the Nevada Revised Statutes ("NRS") (as from time to time amended), provided
        such officer or director acts in good faith and in a manner which such person reasonably believes to be in or not opposed to the best interests of the Registrant, and with respect to any criminal matter, had no reasonable cause to believe such
        person's conduct was unlawful.
NRS 78.7502 states:
"1. A corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action
        by or in the right of the corporation, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
        another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action,
        suit or proceeding if the person:
(a)
Is not liable pursuant to NRS 78.138; or
(b)
Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no
                reasonable cause to believe the conduct was unlawful.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of
nolo contendere
or its equivalent, does not, of itself, create a presumption that the person
        is liable pursuant to NRS 78.138 or did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, or that, with respect to any criminal action or proceeding, he or
        she had reasonable cause to believe that the conduct was unlawful.
2. A corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the
        fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
        other enterprise against expenses, including amounts paid in settlement and attorneys' fees actually and reasonably incurred by the person in connection with the defense or settlement of the action or suit if the person:
(a)
Is not liable pursuant to NRS 78.138; or
(b)
Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation.
Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in
        settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person
        is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.
3. To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections 1 and 2, or in defense of any claim, issue or
        matter therein, the corporation shall indemnify him or her against expenses, including attorneys' fees, actually and reasonably incurred by him or her in connection with the defense."
The Registrant's By-laws also provide that to the fullest extent permitted by NRS 78.751 (as from time to time amended), the Registrant shall pay the expenses of officers and directors of the Corporation incurred in defending a civil or criminal
        action, suit or proceeding, as they are incurred and in advance of the final disposition of such matter, upon receipt of an undertaking in form and substance acceptable to the board of directors for the repayment of such advances if it is
        ultimately determined by a court of competent jurisdiction that the officer or director is not entitled to be indemnified.
NRS 78.751 states:
"1. Any discretionary indemnification pursuant to NRS 78.7502, unless ordered by a court or advanced pursuant to subsection 2, may be made by the corporation only as authorized in the specific case upon a determination that indemnification of
        the director, officer, employee or agent is proper in the circumstances. The determination must be made:
(a)
By the stockholders;
(b)
By the board of directors by majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding;
(c)
If a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion; or
(d)
If a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion.
2. The articles of incorporation, the bylaws or an agreement made by the corporation may provide that the expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the corporation as
        they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent
        jurisdiction that the director or officer is not entitled to be indemnified by the corporation. The provisions of this subsection do not affect any rights to advancement of expenses to which corporate personnel other than directors or officers may
        be entitled under any contract or otherwise by law.
3. The indemnification pursuant to NRS 78.7502 and advancement of expenses authorized in or ordered by a court pursuant to this section:
(a)
Does not exclude any other rights to which a person seeking indemnification or advancement of expenses may be entitled under the articles of incorporation or any bylaw, agreement, vote of stockholders or
                disinterested directors or otherwise, for either an action in the person's official capacity or an action in another capacity while holding office, except that indemnification, unless ordered by a court pursuant to NRS 78.7502 or for the
                advancement of expenses made pursuant to subsection 2, may not be made to or on behalf of any director or officer if a final adjudication establishes that the director's or officer's acts or omissions involved intentional misconduct, fraud
                or a knowing violation of the law and was material to the cause of action. A right to indemnification or to advancement of expenses arising under a provision of the articles of incorporation or any bylaw is not eliminated or impaired by an
                amendment to such provision after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought,
                unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.
(b)
Continues for a person who has ceased to be a director, officer, employee or agent and inures to the benefit of the heirs, executors and administrators of such a person."
In addition, the Registrant maintains directors' and officers' liability insurance which insures against liabilities that its directors and officers may incur in such capacities.
Reference is made to "Undertakings," below, for the Registrant's undertakings in this registration statement with respect to indemnification of liabilities arising under the Securities Act.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
Exhibit
No.
Exhibit
4.1
Deferred Stock Unit Agreement, dated August  31, 2020, between Galectin Therapeutics Inc. and Joel Lewis
                  (Incorporated by reference to the Company's Current Report on Form 8-K as filed with the Commission on September 2, 2020)
5.1*
Opinion of Dentons US LLP regarding legality
23.1*
Consent of Dentons US LLP (included as part of Exhibit 5.1 hereto)
23.2*
Consent of Cherry Bekaert LLP
24*
Power of Attorney (included in the signature pages of this registration statement)
99.1
2019 Omnibus Equity Incentive Plan (Incorporated by reference to Appendix A
                of the Company's Definitive Proxy Statement on Schedule 14A as filed with the Commission on October 17, 2019.)
99.2
Amendment to 2019 Omnibus Equity Incentive Plan (Incorporated by reference to
                Appendix B of the Company's Definitive Proxy Statement on Schedule 14A as filed with the Commission on October 12, 2021.)
107*
Filing Fee Table
*
Filed herewith.
Item 9.
Undertakings.
The undersigned registrant hereby undertakes:
1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
          represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
          that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
          price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however
, that paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those
          paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act, that are incorporated by reference in this registration statement, or is contained in a
          form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and this
          offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;
3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of this offering;
4. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d)
          of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new
          registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
5. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6, or
          otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
          indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
          asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
          appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be
        signed on its behalf by the undersigned, thereunto duly authorized, in the City of Norcross, State of Georgia on March 30, 2023.
GALECTIN THERAPEUTICS INC.
By:
/s/ Joel Lewis
Joel Lewis
Chief Executive Officer and President
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joel Lewis and Jack W. Callicutt and each of them, his or her true and lawful attorneys-in-fact and agents, with
          full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file
          the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and
          every act and thing requisite and necessary to be done in and about the premises, as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her
          substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
PRINCIPAL EXECUTIVE, FINANCIAL & ACCOUNTING OFFICERS AND DIRECTORS
:
Name
Title
Date
/s/ Joel Lewis
Chief Executive Officer (Principal Executive Officer)
March 30, 2023
Joel Lewis
/s/ Jack W. Callicutt
Chief Financial Officer (Principal Financial and Accounting Officer)
March 30, 2023
Jack W. Callicutt
/s/ Richard E. Uihlein
Chairman and Director
March 30, 2023
Richard E. Uihlein
/s/ Gilbert F. Amelio, Ph.D
Director
March 30, 2023
Gilbert F. Amelio, Ph.D.
/s/ James C. Czirr
Director
March 30, 2023
James C. Czirr
/s/ Kary Eldred
Director
March 30, 2023
Kary Eldred
/s/ Kevin D. Freeman
Director
March 30, 2023
Kevin D. Freeman, CFA
/s/ Gilbert S. Omenn
Director
March 30, 2023
Gilbert S. Omenn, M.D., Ph.D.
/s/ Marc Rubin
Director
March 30, 2023
Marc Rubin, M.D.
/s/ Elissa J. Schwartz
Director
March 30, 2023
Elissa J. Schwartz, Ph.D.
/s/ Harold Shlevin
Director
March 30, 2023
Harold Shlevin, Ph.D.
/s/ Richard A. Zordani
Director
March 30, 2023
Richard A. Zordani